STOCK TITAN

Spruce Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company, has announced participation in two investor conferences. CEO Richard King will engage in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 24 at 9:00am PST. Additionally, he will take part in a panel discussion on March 2 at the 41st Cowen Annual Healthcare Conference at 11:10am PST. Interested parties can access live webcasts on the company’s website, with replays available for 30 days.

Positive
  • None.
Negative
  • None.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in two upcoming investor conferences.

10th Annual SVB Leerink Global Healthcare Conference

Chief Executive Officer, Richard King, is scheduled to participate in a fireside chat on Wednesday, February 24 at 9:00am PST / 12:00pm EST.

41st Cowen Annual Healthcare Conference

Richard King is also scheduled to participate in a panel discussion on Tuesday, March 2 at 11:10am PST / 2:10pm EST.

Interested parties can access the live webcast for each conference from the Investor Relations section of the company's website at www.sprucebiosciences.com. A replay of the webcasts will be available after the conclusion of the live presentation for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years.

FAQ

What conferences will Spruce Biosciences participate in?

Spruce Biosciences will participate in the 10th Annual SVB Leerink Global Healthcare Conference on February 24 and the 41st Cowen Annual Healthcare Conference on March 2.

When will Richard King speak at the investor conferences?

Richard King will speak at the 10th Annual SVB Leerink Global Healthcare Conference on February 24 at 9:00am PST and at the 41st Cowen Annual Healthcare Conference on March 2 at 11:10am PST.

How can I access the webcasts for the investor conferences?

The live webcasts for the investor conferences can be accessed from the Investor Relations section of Spruce Biosciences' website.

What is the focus of Spruce Biosciences?

Spruce Biosciences focuses on developing and commercializing novel therapies for rare endocrine disorders, particularly classic congenital adrenal hyperplasia (CAH).

What is the product candidate being developed by Spruce Biosciences?

Spruce Biosciences is developing tildacerfont as a potential first non-steroidal therapy for classic congenital adrenal hyperplasia (CAH).

Spruce Biosciences, Inc.

NASDAQ:SPRB

SPRB Rankings

SPRB Latest News

SPRB Stock Data

20.47M
36.96M
7.73%
41.43%
0.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO